Comparative Pharmacology
Head-to-head clinical analysis: CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER versus CEPHALOTHIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER versus CEPHALOTHIN.
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER vs CEPHALOTHIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Cephalothin is a first-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking peptidoglycan cross-linking. It has activity against gram-positive cocci (e.g., Staphylococcus aureus, Streptococcus pyogenes) and some gram-negative bacilli (e.g., Escherichia coli, Klebsiella pneumoniae).
750 mg to 1.5 g intravenously every 8 hours; for severe infections, up to 1.5 g every 6 hours.
1-2 g IV every 4-6 hours; maximum 12 g/day.
None Documented
None Documented
Terminal elimination half-life: 1.2-1.6 hours (prolonged to 15-22 hours in severe renal impairment, CrCl <10 mL/min); requires dose adjustment in renal failure
0.5-1 hour in patients with normal renal function; prolonged to 2-8 hours in moderate renal impairment (CrCl 30-50 mL/min); up to 20-30 hours in end-stage renal disease; due to rapid elimination, frequent dosing (q4-6h) is required for continuous bactericidal levels.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; fecal: <1%
Primarily renal (60-90% unchanged) via tubular secretion and glomerular filtration; minor biliary excretion (less than 5%); hepatic metabolism to desacetylcephalothin (active but less potent) accounts for about 20-30% of dose; fecal elimination negligible.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic